- Home
- NKSH vs GLSI Comparison
NKSH vs GLSI Comparison
Compare NKSH & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NKSH
- GLSI
- Stock Information
- Founded
- NKSH 1891
- GLSI 2006
- Country
- NKSH United States
- GLSI United States
- Employees
- NKSH N/A
- GLSI N/A
- Industry
- NKSH Major Banks
- GLSI Biotechnology: Pharmaceutical Preparations
- Sector
- NKSH Finance
- GLSI Health Care
- Exchange
- NKSH Nasdaq
- GLSI Nasdaq
- Market Cap
- NKSH 163.0M
- GLSI 134.6M
- IPO Year
- NKSH N/A
- GLSI 2020
- Fundamental
- Price
- NKSH $28.80
- GLSI $11.57
- Analyst Decision
- NKSH Strong Buy
- GLSI Strong Buy
- Analyst Count
- NKSH 1
- GLSI 1
- Target Price
- NKSH $38.00
- GLSI $39.00
- AVG Volume (30 Days)
- NKSH 15.4K
- GLSI 85.4K
- Earning Date
- NKSH 08-13-2025
- GLSI 08-13-2025
- Dividend Yield
- NKSH 5.24%
- GLSI N/A
- EPS Growth
- NKSH N/A
- GLSI N/A
- EPS
- NKSH 1.77
- GLSI N/A
- Revenue
- NKSH $49,801,000.00
- GLSI N/A
- Revenue This Year
- NKSH N/A
- GLSI N/A
- Revenue Next Year
- NKSH $5.93
- GLSI N/A
- P/E Ratio
- NKSH $16.24
- GLSI N/A
- Revenue Growth
- NKSH 2.21
- GLSI N/A
- 52 Week Low
- NKSH $23.75
- GLSI $8.06
- 52 Week High
- NKSH $33.37
- GLSI $17.00
- Technical
- Relative Strength Index (RSI)
- NKSH 53.90
- GLSI 60.72
- Support Level
- NKSH $28.01
- GLSI $11.06
- Resistance Level
- NKSH $29.64
- GLSI $12.54
- Average True Range (ATR)
- NKSH 0.65
- GLSI 0.75
- MACD
- NKSH -0.09
- GLSI 0.07
- Stochastic Oscillator
- NKSH 40.51
- GLSI 61.81
About NKSH National Bankshares Inc.
National Bankshares Inc is a bank holding company. It focuses on lending to small and mid-sized businesses and individuals. The types of loans it offers include commercial and agricultural, commercial real estate, construction for commercial and residential properties, residential real estate, home equity, and various consumer loan products. It also operates an insurance and brokerage subsidiary, National Bankshares Financial Services, Inc. The company earns its revenues from interest and fees on loans, non-interest income, and investments.
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.